Biodexa Pharmaceuticals and SXT Pharmaceuticals Lead Short Interest Among Sub-$2B Healthcare Stocks
Recent short interest data from late October 2026 reveals significant bearish sentiment within the sub-$2 billion healthcare sector. Investors are heavily betting against high-volatility biotechnology and pharmaceutical companies, signaling caution regarding clinical or market outcomes for smaller-cap players. Biodexa Pharmaceuticals (BDRX) and China SXT Pharmaceuticals (SXTC) have emerged as the most shorted entities in this category. This concentration of short positions suggests that market participants are anticipating downward price pressure or significant volatility for these specific biotech firms.